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ABSTRACT 
C75 is a synthetic anticancer drug that inhibits fatty acid synthase (FAS) and shows a 
potent anorexigenic side effect. In order to find new cytotoxic compounds that do not 
impact food intake, we synthesized a new family of C75 derivatives. The most 
promising anticancer compound among them was UB006 ((4SR,5SR)-4-
(hydroxymethyl)-3-methylene-5-octyldihydrofuran-2(3H)-one). The effects of this 
compound on cytotoxicity, food intake and body weight were studied in UB006 racemic 
mixture and in both its enantiomers separately. The results showed that both 
enantiomers inhibit FAS activity and have potent cytotoxic effects in several tumour 
cell lines, such as the ovarian cell cancer line OVCAR-3. The (-)-UB006 enantiomer’s 
cytotoxic effect on OVCAR-3 was 40-fold higher than that of racemic C75, and 2- and 
38-fold higher than that of the racemic mixture and its opposite enantiomer, 
respectively. This cytotoxic effect on the OVCAR-3 cell line involves mechanisms that 
reduce mitochondrial respiratory capacity and ATP production, DDIT4/REDD1 
upregulation, mTOR activity inhibition, and caspase-3 activation, resulting in apoptosis. 
In addition, central and peripheral administration of (+)-UB006 or (-)-UB006 into rats 
and mice did not affect food intake or body weight. Altogether, our data support the 
discovery of a new potential anticancer compound (-)-UB006 that has no anorexigenic 
side effects.  
3	  
	  
 
Keywords: FAS fatty acid synthase, C75 derivatives, CPT1 carnitine palmitoyltransferase 1, 
ovarian cell cancer 
Abbreviations:  
18S, 18S ribosomal RNA; BIP, binding immunoglobulin protein; BSA, bovine serum 
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DNA-damage-inducible transcript 4/ regulated in development and DNA damage 
responses 1 protein; DMSO,  dimethyl sulfoxide; ETC, electron transport chain; FAO, 
fatty acid β-oxidation; FAS, fatty acid synthase; FCCP, carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone; i.c.v., intracerebroventricular; i.p., intraperitoneal; 
IC50, half maximal inhibitory concentration; LCFA, long chain fatty acid; mTOR, 
mammalian target of rapamycin; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide; OCR, oxygen consumption rate; TIM-44, translocase of 
the mitochondrial inner membrane. 
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1. INTRODUCTION 
 Tumour cells present a typical phenotype of abnormally elevated fatty acid 
synthase (FAS) activity, which indicates that this enzyme is a good target for treating 
some malignancies [1,2]. FAS catalyses fatty acid synthesis from the substrates acetyl-
CoA and malonyl-CoA [3]. There is increased interest in finding novel FAS inhibitors 
as antitumor drugs and many compounds have been evaluated for their cytotoxic 
capacity [4,5]. Among them, C75 is a chemically stable inhibitor of FAS that binds to 
the enzyme and inhibits its activity [6]. This synthetic compound has antitumor activity 
in cell lines and animal models, through mechanisms that reduce lipid synthesis and 
increase apoptosis [1,7].  
 Inside the cell, C75 is converted into its coenzyme A derivative, C75-CoA, a 
potent inhibitor of carnitine palmitoyltransferase 1 (CPT1) [8,9]. CPT1 catalyses the 
first step in the transport of long-chain fatty acyl-CoA (LFCA-CoA) from the cytoplasm 
to the mitochondria, which is the rate-limiting step in fatty acid β-oxidation (FAO) [10]. 
Due to its dual inhibitory effect on FA synthesis (FAS inhibition) and FA oxidation 
(CPT1 inhibition), C75 has antitumor activity. However, C75 also has undesirable side 
effects that limit its use for cancer therapy. C75 crosses the blood-brain barrier and 
affects the central nervous system. In the hypothalamus, the presence of the CoA 
derivative C75-CoA in the cell causes a profound reduction in food intake and drop in 
body weight in rodents, through CPT1 inhibition [9]. Therefore, appetite suppression 
and weight loss are undesirable side effects of the use of this drug in cancer therapy.  
 It is well-known that the stereochemistry of a drug could determine its biological 
activity [11,12]. The preparation of (-)-C75 and (+)-C75 enantiomers separately was 
not reported until recently [13]. We have previously shown that (-)-C75 inhibits FAS 
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activity in vitro and has cytotoxic effects on tumour cell lines, whereas (+)-C75 inhibits 
CPT1 in vitro and its administration to rodents produces anorexia [14]. 
  The aim of this study was to investigate whether a modification in the C75 
structure could lead to changes in its pharmacological activity, particularly in relation to 
its antitumor properties. We synthesized a series of new compounds that are structurally 
related to C75. Here we describe de novo synthesis of three alcohol C75 derivatives: 
(4SR,5SR)-4-(hydroxymethyl)-3-methylene-5-octyldihydrofuran-2(3H)-one, also called 
(±)-UB006, and its two homologues (±)-UB339 (one carbon extra) and (±)-UB340 (2 
carbons extra). Based on our previous experience of the stereoselective synthesis of 
paraconic acids [15], we also synthesized both enantiomers of UB006 separately to 
study possible differences in their biological properties (Fig. 1).  
 
Figure 1. Structure of (±)-UB006, (-)-UB006, (+)-UB006, (±)-UB339, (±)-UB340 and 
(±)-C75  
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2. RESULTS AND DISCUSSION 
2.1. Synthesis of new drugs  
2.1.1. Synthesis of (±)-UB006  
C75 was used as a starting material for the synthesis of (±)-UB006 (Fig. 2). In 
the first step, the exocyclic double bond was protected by a selenoether derivative. 
Then, the carboxylic group was reduced with borane, and finally the double bond was 
recovered under oxidizing conditions. 
	  
Figure 2. Synthesis of (±)-UB006 
  
2.1.2. Synthesis of (-)-UB006 and (+)-UB006 
We used two different routes to synthesize the enantiomers of UB006 (Fig. 3). In 
the first route, the enantiomers of C75 were used as a starting material [14], and the 
subsequent protocol was identical to those reported for the racemic mixture. The second 
route was more straightforward. In our previous studies, we obtained a useful chiral g-
butyrolactone [14]. We reductively cleaved this compound using NaBH4 as a mild 
reagent. Next, we achieved α-methylenation of the resulting lactone by Greene’s 
procedure [16], to yield (–)-UB006 (or (+)-UB006.  
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Figure 3. Synthesis of (–)-UB006  
	  
2.1.3. Synthesis of (±)-UB339  
Lactone formation of (±)-UB339 was accomplished through Parker’s protocol 
[17] from nonanoic anhydride and tricarballylic acid (Fig. 4). The carboxylic group was 
selectively reduced as explained before. We obtained the desired compound using 
borane, followed by α-methylenation of the resulting alcohol. 
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Figure 4. Synthesis of (±)-UB339 
	  
2.1.4. Synthesis of (±)-UB340  
The synthesis of (±)-UB340 (Fig. 5) was started by known free radical addition 
of nonanal to dimethyl maleate [18]. Then, in three steps, we transformed the adduct to 
a functionalized trans butyrolactone bearing a methyl ester in b and a nonanyl group in 
g. The methyl ester was hydrolysed in basic media without any appreciable 
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isomerization to the cis lactone. The carboxylic acid functionality was further changed 
to aldehyde by borane-mediated reduction, followed by Swern oxidation. Two-carbon 
homologation was carried out by a Wittig reaction using commercially available 
phosphorane to produce E olefin. In the next two steps, we hydrolysed tert-butyl ester 
and reduced the double bond with H2/Pd. After that, we introduced a methylene group 
in the α position, and protected it with a selenoether derivate, which allowed us to 
reduce the carboxylic group with borane. In the final step, the double bond was 
recovered under oxidizing conditions. 
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Figure 5. Synthesis of (±)-UB340 
	  
2.2. Inhibitory effect on in vitro FAS activity  
We analysed the effect of the racemic mixtures of UB006, UB339 and UB340 
and of the separated UB006 enantiomers on FAS activity. (±)-UB006 and its separated 
enantiomers inhibited FAS, but the (-)-UB006 form showed stronger inhibitory activity 
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than the (+) enantiomer or the racemic form (Fig. 6A). The (±)-UB339 and (±)-UB340 
forms exhibited lower inhibitory activity on FAS than UB006 (Fig. 6B). Since our 
measure of IC50 of (–)-C75 was 460±44 µM [14], the data demonstrated that the (-)-
UB006 form, IC50 220±58, was a stronger FAS inhibitor than the other two UB006 
chemicals or (–)-C75 (Fig. 6A and B). As expected, the results demonstrate that both 
enantiomers show different quantitative actions. While (-)-UB006 inhibits FAS in vitro 
with an IC50 value of 220 µM, the (+)-UB006 enantiomer has an IC50 value of 470 µM, 
which is close to that of racemic C75 with an IC50 value of 498 µM. In addition, UB006 
homologues (±)-UB340 and (±)-UB339 showed less FAS inhibitory 
activity.
 
Figure 6. Effects of (±)-UB006, (+)-UB006, (-)-UB006, (±)-UB339 and (±)-UB340 on 
in vitro FAS activity. (A) Cytosolic hepatic extracts (315 µg) obtained from rat were 
preincubated for 30 min with increasing concentrations of (±)-UB006, (+)-UB006, (-)-
UB006, (B) (±)-UB339 and (±)-UB340. FAS activity was measured and IC50 were 
calculated. Data are expressed as the mean ± SEM. 
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2.3. Cytotoxic effect on tumour cell lines  
Normal tissues have low levels of fatty acid synthesis. However, some 
malignancies and their precursor lesions show high levels of FAS expression, which 
suggests that FAS is a target for anticancer drug development [1,7,19]. After the in vitro 
analysis of (+)-UB006, (-)-UB006, (±)-UB006, (±)-UB339 and (±)-UB340 on FAS 
activity, we studied the effect of these drugs on tumour cell viability. It has been 
reported that the inhibition of FAS in cancer cells diminishes their viability and has a 
cytotoxic effect. To this aim, cytotoxicity assays were performed with human cancer 
cell lines from different tissues: SKBr3, OVCAR3, HCT116, MCF-7, MiaPaca2 and 
MDA-MB-231, with different levels of FAS expression (Fig. 7) [1,20], and 
consequently different sensitivity to FAS inhibitors. Therefore, we performed an MTT 
cytotoxic assay with these seven cancer cell lines and fibroblasts as a control (Table 1).  
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Figure 7. Analysis of FAS protein levels in different cancer cell lines and fibroblasts. 
(A) 30 ug of cytosolic extracts of the each cell line were used for the Western blot 
analysis. (B) Relative protein quantification. 
The results of the MTT cytotoxic assay showed that all racemic alcohols, (±)-
UB006, (±)-UB339 and (±)-UB340 were better cytotoxic agents than (–)-C75 in all cell 
lines used in this study. Interestingly, enantiomers of UB006 had different effects on 
cell viability (Table 1). We observed that (-)-UB006, the enantiomer showing stronger 
FAS inhibitory properties, had a cytotoxic effect on SKBr3, OVCAR3, HCT116, MCF-
7, MiaPaca2 and MDA-MB-231 tumour cell lines with IC50 of 1.0, 0.5, 6.5, 15.0, 9.8, 
and 17.9 µM, respectively. All these IC50 values were lower than those determined for 
(–)-C75 (Table 1). (-)-UB006, with an IC50 of 1.0 (SKBR3) and 0.5 µM (OVCAR3), 
was almost 40 times more active than (–)-C75. However, (+)-UB006 had a higher IC50 
in the cell lines tested than the (–) enantiomer. These results suggest that (-)-UB006 
could be a good candidate for the treatment of some malignancies, because of its 
cytotoxic effect on tumour cells, particularly OVCAR3 cells whose IC50 value reached 
the minimum of 500 nM. A comparison of these IC50 values with those obtained by 
treating the cells with (–)-C75 shows the much stronger power of (-)-UB006 to act as 
an antitumor agent. This is especially relevant, as racemic C75 is considered a good 
candidate for improving cancer treatment [21]. 
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Cell line SKBR3 OVCAR3 HCT116 MCF-7 MiaPaca2 PC3 MDA-
MB-231 
Fibroblasts 
         
Compound  IC50 (µM) 
C75 19.8±1.8 21.9±3.9 46.4±5.7 27.3±1.8 21.8±0.9 26.8±3.1 43.8±1.8 63.2±10.5 
(-)-C75 38.2±1.4 17.9±2.7 74.8±2.3 46.4±2.3 25.3±1.6 34.3±1.6 57.7±0.4 >117 
(±)-UB006 3.7±1.7 1.1±0.3 18.5±1.3 26.5±2.2 13.1±0.4 10.0±1.9 11.8±1.3 11.6±0.8 
(-)-UB006 1.0±0.3 0.5±0.3 6.5±0.7 15.0±1.6 9.8±1.0 N.D 17.9±1.3 22.4±1.2 
(+)-UB006 4.7±0.2 19.4±2.5 15.9±1.4 40.1 ±3.0 30.7±1.4 24.2±1.5 36.8±0.8 47.8±1.3 
(±)-UB339 5.5±0.5 6.9±1.6 N.D 17.6±1.6 12.4±0.5 N.D 27.2±0.7 24.9±0.8 
(±)-UB340 5.4±0.8 1.1±0.3 N.D 16.0±1.6 8.9±1.0 N.D 14.2±0.5 17.0±0.4 
 
Table 1. Effect of (-)-C75, (±)-UB006, (+)-UB006, (-)-UB006, (±)-UB339 and UB340 
on MCF-7, SKBr3, Ovcar-3, MiaPaca2, PC3, HCT116 and MDA-MB-231 cell viability. 
To calculate IC50, cells were incubated for 72h with increasing concentrations of the 
compounds. Drug cytotoxicity was determined using a standard colorimetric MTT 
assay. Data are expressed as the mean ± SEM. N.D = not determined. 
 
2.4. Effect on fatty acid synthesis 
It has been reported that (±)-C75 inhibits fatty acid synthesis, measured as the 
incorporation of [U14C]acetate into total lipids [22–24]. We demonstrated that the newly 
synthesized FAS inhibitors, (-)-UB006 and (+)-UB006, inhibited fatty acid synthesis 
pathway activity in the OVCAR3 cell more than (±)-C75. (-)-UB006 and (+)-UB006, at 
2 µg/ mL concentration, produced an 85% and 68% reduction in fatty acid synthesis 
13	  
	  
activity respectively (Fig. 8), while the reduction produced by 8 µg/ mL of racemic C75 
was 38%. Next, we confirmed that the observed effect of (-)-UB006 on fatty acid 
synthesis reduction is correlated with FAS inhibition. We achieved this by analysing 
FAS activity in OVCAR3 cells after 2-hour (-)-UB006 treatment or DMSO treatment. 
(-)-UB006 inhibits FAS activity by 24.1%. FAS activity in OVCAR3 cells was 
23.6±1.9 pmol/min/mg prot after DMSO treatment, and 17.9±1.3 pmol/min/mg prot 
after (-)-UB006 treatment.  
 
Figure 8. Effects of (+)-UB006, (-)-UB006 and (±)-C75 on fatty acid synthesis of 
OVCAR3 cells. OVCAR3 cells were incubated with different concentrations of (+)-
UB006, (-)-UB006, (±)-C75 and DMSO as a control. After the addition of sodium [U-
14C]-acetate, lipids were extracted and the incorporation of 14C was measured.  
 
Our data agree with those of studies on other FAS inhibitors [25] of lipid 
biosynthesis, which deplete the palmitate and palmitate-derived lipids required in 
multiple cellular processes for tumour cell growth, proliferation and survival.  
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2.5. Effect of (-)-UB006 on apoptosis  
It has been described that FAS inhibitors trigger cell death by apoptotic 
mechanisms [25,26]. In an attempt to elucidate the mechanism of action of (-)-UB006, 
we first measured the mRNA expression of apoptotic-marker caspase-3 and ER stress 
chaperone BiP or energy stress factor DDIT4/REDD1 [27] (Fig. 9). While BiP mRNA 
levels remained unchanged, we observed a 20% increase in caspase-3 mRNA levels and 
a remarkable 25-fold increase in DDIT4/REDD1 mRNA levels. DDIT4/REDD1 is an 
inducer of apoptosis [26]. In a recent study, this factor was involved in the induction of 
ovarian cancer cell death by activating apoptosis [26]. These authors demonstrated that 
orlistat, an inhibitor of FAS, mediates its apoptotic action by inducing DDIT4/REDD1, 
which in turn inhibits the mTOR pathway and cell proliferation, and activates 2-, 8-, 9- 
and 3-caspases, all resulting in cell death.  
 
Figure 9. Analysis of mRNA levels of caspase-3, DDIT4/REDD1 and ER stress Bip 
factor by qRT-PCR in OVCAR3 after (-)-UB006 treatment. 
 
The induction of apoptosis was confirmed by Western blot, through assessing 
caspase-3 cleavage. In line with the high upregulation of DDIT4/REDD1, we observed 
increased activation in both caspases (Fig. 10).  
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Figure 10. Analysis of the activation of caspase-3 in OVCAR3 cell line after (-)-UB006 
treatment by Western blot. Analysis of TIM-44 protein levels as a mitochondrial protein 
control. 
  
Furthermore, DDIT4/REDD1 is known to inhibit the mTOR pathway and cell 
proliferation [27]. To evaluate mTOR activity, we assessed the phosphorylation levels 
of mTOR substrate p70 S6 kinase. (–)-UB006 tends to reduce the S6K1 kinase 
phosphorylation level (Fig. 11), which might be due to the inhibition of mTOR activity, 
as a result of upregulated DDIT4/REDD1. Our results agree with the aforementioned 
findings [26]: treatment of OVCAR3 with (-)-UB006 increased DDIT4/REDD1 mRNA 
levels, which is correlated with decreased S6 kinase phosphorylation and mTOR 
inhibition. Concomitant with the increase in REDD1 expression, we also observed that 
caspase-3, which is required for robust death of ovarian cancer cells, is activated by (-)-
UB006 treatment.  
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Figure 11. Effect of (-)-UB006 on mTOR activity analysed by measuring mTOR 
substrate phosphorylation S6K(T389) levels by Western blot. 
 
2.7. Effect of (-)-UB006 in the metabolic extracellular flux analysis  
Considering that DDIT4/REDD1 is a factor that is responsive to energy stress, 
we aimed to assess whether mitochondrial function was altered in OVCAR3 cells 
treated with (–)-UB006. We analysed metabolic extracellular flux changes produced by 
(–)-UB006 incubation. Mitochondrial respiration was reduced by 48.8% in OVCAR3 
cells treated with (–)-UB006 (Fig. 12A and C). Interestingly, we observed a decrease in 
ATP production (Fig. 12D) and proton leak (Fig. 12E). When we analysed 
mitochondrial oxygen consumption ratios, (–)-UB006 did not change the percentages 
attributable to ATP-linked OCR, proton leak and spare capacity (Fig. 12B). However, 
when non-mitochondrial respiration was taken into account, there was a clear reduction 
in the percentage of mitochondrial oxygen consumption. These data suggest an overall 
reduction in mitochondrial function, regardless of the processes in which oxygen is 
consumed (Fig. 12B). Moreover, mitochondrion-dependent spare respiratory capacity is 
reduced in treated OVCAR3 cells (Fig. 12F and G). Nonetheless, non-mitochondrial 
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respiration remains unaltered (Fig. 12H), which suggests that only oxygen-consuming 
processes in mitochondria are affected. These energy disturbances might be the 
processes that trigger DDIT4/REDD1 upregulation and the consequent activation of 
apoptosis [28]. 
 
Figure 12. (-)-UB006 effect on mitochondria bioenergetic profile in OVCAR3 cells. (A) 
The injection of inhibitors over time is represented with lines, and their effect on the 
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average OCR trace is studied in the bioenergetic profile. (B) The ratios of the 
parameters are calculated for total OCR (bigger circles) and mitochondrial OCR 
(smaller circles). Taking into account the bioenergetic data, we calculated (C) basal 
mitochondrial oxygen consumption, (D) ATP-linked OCR and (E) proton leak after the 
addition of 2 µg/mL oligomycin. (F) Maximum respiratory rate and (G) spare capacity 
were calculated after the injection of 0.3 µM FCCP. Finally, 1 µM antimycin A was 
added to measure (H) non-mitochondrial respiration. The results are represented as 
mean ± SEM. p<0.05. 
 
 Although we do not know what triggers the energy depletion, we can speculate 
that it could be the result of a decreased amount of substrate (FA) and malonyl-CoA 
accumulation, both due to FAS inhibition. Alternatively, it has been described in HeLa 
cells that caspase-3 cleavage inhibits complexes I and II, which leads to a loss of 
mitochondrial function [29]. We cannot discard the possibility that the mitochondrial 
function loss observed in our model is triggered by caspase-3 activation. 
 
2.8. Effect on CPT1 activity 
One of the problems of using C75 as an anticancer drug is the undesirable side 
effect of reduction in body weight and appetite [30,31]. In fact, several laboratories are 
investigating the synthesis of FAS inhibitors that do not cause anorexia and a reduction 
in body weight [32]. It is known that the central nervous system (CNS) controls appetite 
and the maintenance of energy balance, and that lipid metabolism in hypothalamic 
neurons is crucial in mediating these actions [33,34]. C75 can modulate the activity of 
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enzymes involved in lipid metabolism, such as FAS [6] and CPT1 [8]. C75 is an 
inhibitor of FAS in vitro, and its inhibition in the hypothalamus could lead to an 
increase in malonyl-CoA levels, which, as a physiological inhibitor of CPT1, prevents 
the oxidation of newly synthesized FA. Both malonyl-CoA and LCFA-CoA have been 
proposed as molecular signals that control food intake and body weight [35,36]. Besides 
the effect on FAS activity, in a previous study we showed that C75-CoA is a potent 
inhibitor of CPT1, and that the hypothalamus can form the CoA adduct form of C75, 
that is, C75-CoA. In addition, we showed that hypothalamic C75-CoA actually inhibits 
CPT1 [9].  
Since inhibition of CPT1 in the hypothalamus causes a decrease in food intake, 
we first analysed the effect of racemic (±)-UB006-CoA on CPT1 activity in vitro to 
determine whether it could act as a potential food intake regulator. (±)-UB006-CoA was 
prepared using (±)-UB006 and coenzyme A in slightly basic D2O, as in previous 
descriptions [9,14]. Our results show that (±)-UB006 is a much weaker inhibitor of 
CPT1 activity in vitro than (±)-C75-CoA, with IC50 > 10 µM (Fig. 13). 
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Figure 13. Effect of (±)-C75-CoA and (±)-UB006-CoA on CPT1 activity. Mitochondrial 
extracts (3-4 µg) from yeast expressing CPT1A-wt were preincubated for 5 min with 
increasing concentrations of (±)-C75-CoA and (±)-UB006-CoA, then CPT1 activity was 
measured and IC50 were calculated. 
 
2.9. Effect of (-)-UB006 on food intake and body weight 
Once we had synthesized both UB006 enantiomers separately, we analysed the 
effect of i.c.v. injection of these enantiomers on food intake and body weight. Male 
adult Sprague-Dawley rats received i.c.v. injections of (+)-UB006, (−)-UB006 or a 
vehicle (control animals). (±)-C75 was used as a control [9].  
Consistent with previous results [8], (±)-C75 produced a decrease in body 
weight (Fig. 14A) and food intake (Fig. 14B). However, neither of the two compounds, 
(+)-UB006 or (−)-UB006, caused significant weight loss over three days. 
We also investigated the peripheral action of both enantiomers of UB006. Male 
mice received i.p. injections (15 mg/kg/day) of (+)-UB006, or (−)-UB006, or a vehicle 
(control animals) or (±)-C75 (as a control). Similarly to the results of the i.c.v. 
injections, peripheral administration of the enantiomers did not affect body weight (Fig. 
14C) or food intake (Fig. 14D) during the three-day treatment. Consistent with previous 
work, (±)-C75 produced a decrease in food intake and body weight, and after 2 days of 
treatment the animals exhibited resistance to C75-induced anorexia. 
 UB006, a novel derivative of C75 presents greatly enhanced potency as a 
cytotoxic agent, without affecting body weight. UB006-CoA produced by the reaction 
of (±)-UB006 with HSCoA does not inhibit CPT1 and does not produce weight lost in 
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animals. Both enantiomers of UB006 affect FAS activity and have cytotoxic activity. 
However, (–)-UB006 shows 40-fold higher activity than its (+)-enantiomer or C75. (-)-
Consequently, UB006 should be examined in depth for cancer treatment. 
 
Figure 14. Effect of (±)-C75, (+)-UB006 and (-)-UB006 on body weight and food 
intake after i.c.v. and i.p. injection. (A) Body weight change measured in rats for 3 days 
every day after a unique i.c.v. injection of (±)-C75 (n = 8), (+)-UB006 (n = 8) and (-)-
UB006 (n = 8) and control injections (n = 9; RPMI 1640 medium as a control). (B) 
Food intake measured in rats 1, 2, 4 and 22 h after i.c.v. injection as in (A). (C) The 
body weight change and (D) food intake measured in mice after daily i.p. injection (15 
mg/kg) (±)-C75, (+)-UB006 and (-)-UB006 and control injections (DMSO dissolved in 
RPMI 1640 medium as a control). N=10; * P < 0.05.  
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 UB006, a novel derivative of C75, presents greatly improved potency as a 
cytotoxic agent without affecting body weight. UB006-CoA produced by the reaction of 
(±)-UB006 with HSCoA does not inhibit CPT1 and does not produce weight loss in 
animals. Both enantiomers of UB006 affect FAS activity and have cytotoxic activity. 
However, (–)-UB006 shows 40-fold more activity than its (+)-enantiomer and C75. (-)-
UB006 should be examined in depth for cancer treatment.  
The present data demonstrate that racemic UB006-CoA cannot suppress CPT1 
activity in vitro, and that neither of the two enantiomers of UB006 reduce food intake 
and body weight. Traditionally, the central effect of C75 on food intake has been 
attributed to FAS inhibition, but in our conditions, despite in vitro inhibition of FAS by 
UB006, this compound did not inhibit food intake or body weight. These results with 
the new compound UB006 confirm what we formerly observed: inhibition of 
hypothalamic FAS is not essential to reduce food intake [14]. In contrast, FAS 
inhibition produced a decrease in tumour development. Tumour cells died at increasing 
concentrations of either racemic UB006 or (-)-UB006.  
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3. CONCLUSIONS 
 We conclude that (-)-UB006 shows higher cytotoxic activity and specificity 
than C75. UB006 racemic and its enantiomers show inhibitory properties towards FAS. 
The incorporation of a hydroxyl group rather than maintaining the carboxylic group of 
C75 increases the inhibition of FAS and antitumor pharmacological action. (-)-UB006 
acted as a strong FAS inhibitor and antitumor agent in vitro, but did not show 
anorexigenic effect when administered to animals. Moreover, (±)-UB006-CoA did not 
inhibit CPT1, which supports our previous results in which inhibition of CPT1, but not 
FAS, seems to be crucial in the central anorectic effect of C75. Altogether, these data 
provide further evidence that the use of the appropriate enantiomer significantly 
improves the effect of the racemic mixture (±)-UB006. The fact that (-)-UB006 has 
cytotoxic, but not anorexic, activity makes it a good candidate for the treatment of some 
types of cancer and encourages future synthesis of new, more specific drugs for the 
treatment of cancer. 
 
4. MATERIAL AND METHODS 
4.1. Materials 
L-[Methyl-3H]carnitine hydrochloride was purchased from Amersham 
Biosciences (GE Healthcare, Barcelona, Spain). [U-14C]-acetate, [Malonyl-2-14C]- 
malonyl-coenzyme A was from PerkinElmer Health Sciences (Boston, USA). Yeast 
culture media products were from DifcoTM Laboratories (Detroit, USA). Bradford 
solution for protein assays was from Bio-Rad Laboratories (Barcelona, Spain). RPMI 
1640 was from Gibco-Invitrogen Corporation (Barcelona, Spain). Defatted bovine 
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serum albumin (BSA), palmitoyl-CoA, malonyl-CoA, (3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) and other chemicals were from Sigma-Aldrich 
(Madrid, Spain). (–)-C75 and (+)-C75 were prepared according to a known procedure 
[14]. 
4.2. Animals and treatments 
Sprague-Dawley male rats (260–290 g) and C57/BL6J male mice (20–23 g) 
were purchased from Janvier. Animals were maintained under a 12 h dark/light cycle 
with free access to food and water. In accordance with current legislation, the Animal 
Ethics Committee at the University of Barcelona approved all experimental protocols. 
After a 1-week acclimation period, chronic i.c.v. cannula were stereotaxically 
implanted into the lateral ventricle of rats under ketamine (Imalgene, 90 mg/kg) and 
xylazine (Rompun, 11 mg/kg) anesthesia. The coordinates were 1.0 mm posterior to 
bregma, 1.4 mm lateral of the sagittal sinus and 4 mm ventral to the dura mater [37]. 
Analgesics (buprenorphine, 0.3 mg/400 mL) and antibiotics (enrofloxacin, 10%) were 
added to the water for 7 days after surgery. 
I.c.v. injections (10 µL, 33 mM final concentrations in RPMI 1640 medium) of 
(±) -C75, (+)-UB006, (−)-UB006 or vehicle (RMPI 1640) were performed with a 
microliter syringe (Hamilton) after 1 week of postsurgical recovery. For the feeding 
experiments, the rats received single injections of vehicle or compound dissolved in 
vehicle 30 min before the light was turned off. We measured intake of chow, corrected 
for spillage, at 1, 2, 4 and 22 h. Body weight was measured after 22 h.  
I.p. injections of (±)-C75, (+)-UB006, (−)-UB006 (100 µL in RPMI 1640 
medium, 15 mg/kg) or vehicle were performed in mice 3 h before the light was turned 
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off (17:00 h) every day, for 3 days. Body weight and food intake were measured after 
every injection. 
4.3. Statistical analysis 
Data are expressed as the mean ± SEM. The significance of differences was 
assessed using the unpaired Student’s t-test. 
4.4. Synthesis of compounds 
4.4.1. Synthesis of (–)-UB006 via selenoether derivative 
(2S,3R,4R)-2-Octyl-5-oxo-4-((phenylselanyl)methyl)tetrahydrofuran-3-carboxylic acid, 
(–)-3:  
A solution of (−)-C75 (0.200 g, 0.78 mmol) in EtOH (3 mL), was added dropwise via 
cannula to a mixture of Ph2Se2 (0.135 g, 0.43 mmol) and NaBH4 (0.035 g, 0.94 mmol) 
in EtOH (3 mL) under N2 at r.t. The resulting yellow solution was stirred for 3.5 h and 
HCl 2 N was added until pH = 1. Then, the volatiles were evaporated and the aqueous 
residue was extracted with CH2Cl2 (3 x 8 mL). The combined organic extracts were 
washed with NH4Cl 20% (2 x 5 mL) and NaCl sat. (2 x 5 mL), H2O (5 mL), dried 
(MgSO4), and the solvent was removed under vacuum. Purification of the residue by 
flash chromatography (hexane/AcOEt/AcOH 70:30:1) produced the desired product 
(0.224 g, 0.55 mmol, 70%). White solid; mp: 116-118ºC; Rf = 0.44 (CH2Cl2/MeOH 
9:1); [α]D = –52.3 (c 1.0, CHCl3); 1H NMR (CDCl3, 400 MHz): δ 7.45-7.43 (m, 2H), 
7.19-7.17 (m, 3H), 4.37 (td, J = 8.8, 4.0, 1H), 3.38-3.32 (m, 1H), 3.15-3.09 (m, 1H), 
3.03 (dd, J = 9.2, 10.2, 1H), 1.80-1.72 (m, 2H), 1.70-1.61 (m, 2H), 1.48-1.16 (m, 12H), 
0.81 (t, J = 6.6, 3H); 13C NMR (CDCl3, 101 MHz): δ 176.2, 174.7, 133.0, 129.3, 129.0, 
127.6, 79.7, 51.3, 45.3, 34.9, 31.8, 29.3, 29.2, 29.1, 26.9, 25.1, 22.6, 14.0; IR (KBr): 
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2951, 2922, 2852, 1763, 1697, 1162; HRMS (ESI+) calculated for C20H28NaO4Se 
[M+Na]+ = 435.1045, found = 435.1039.  
(3R,4S,5S)-4-(Hydroxymethyl)-5-octyl-3-((phenylselanyl)methyl)dihydrofuran-2(3H)-
one, (–)-4: 
BH3:SMe2 (0.066 mL, 0.66 mmol) was added under N2 at –20ºC to a solution of 
(2S,3R,4R)-2-octyl-5-oxo-4-((phenylselanyl)methyl)tetrahydrofuran-3-carboxylic acid 
(0.210 g, 0.51 mmol) in THF anh. (3.5 mL). The resulting mixture was stirred at –20ºC 
for 1 h, 0 ºC for 3 h, and r.t. for 18 h. Then, CH2Cl2 (10 mL), buffer pH = 7 and NH4Cl 
sat. at 0ºC were slowly added and stirred for 15 min at 0ºC and 10 min at r.t. The layers 
were separated and the aqueous layer was extracted with CH2Cl2 (3 x 5 mL). 
Subsequently, the combined organic extracts were washed with NaCl (5 mL), dried 
(MgSO4), and concentrated under reduced pressure. Purification of the residue by flash 
chromatography (hexane/AcOEt 75:25) afforded the desired product (0.160 g, 0.403 
mmol, 79%). Oil; Rf = 0.16 (hexane/AcOEt 80:20); [α]D = –53.5 (c 1.0, CHCl3); 1H 
NMR (300 MHz, CDCl3): δ 7.60-7.49 (m, 2H), 7.26 (s, 3H), 4.23 (td, J = 8.4, 3.6, 1H), 
3.80-3.66 (m, 2H), 3.47 (dd, J = 12.8, 3.9, 1H), 3.06 (dd, J = 12.8, 7.8, 1H), 2.94 (ddd, 
J = 10.0, 7.8, 3.9, 1H), 2.28-2.16 (m, 1H), 1.79-1.14 (m, 14H), 0.88 (t, J = 6.7, 3H); 13C 
NMR (101 MHz, CDCl3): δ 176.9, 132.8, 129.4, 127.5, 80.6, 61.2, 49.0, 43.3, 34.8, 
31.8, 29.4, 29.3, 29.1, 27.2, 25.6, 22.6, 14.0; IR (film): 3468, 2924, 2853, 1755, 1467; 
HRMS (ESI+) calculated for C20H30O3NaSe [M+Na]+ = 421.1252, found 421.1255. 
(4S,5S)-4-(Hydroxymethyl)-3-methylene-5-octyldihydrofuran-2(3H)-one, (-)-UB006: 
H2O2 30% (0.122 mL, 1.076 mmol) at r.t. was added to a solution of (3R,4S,5S)-4-
(hydroxymethyl)-5-octyl-3-((phenylselanyl)methyl) dihydrofuran-2(3H)-one (0.107 g, 
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0.269 mmol) in THF anh. (1 mL). The resulting mixture was stirred for 3 h and then 
CH2Cl2 (5 mL) and H2O (3 mL) were added. The aqueous layer was extracted with 
CH2Cl2 (2 x 5 mL) and combined organic extracts were washed with Na2SO3 (3 mL), 
dried (MgSO4), and concentrated under reduced pressure. Purification of the residue by 
flash chromatography (hexane/AcOEt 60:40) yielded the desired product (0.060 g, 0.25 
mmol, 93%). Oil; Rf = 0.28 (CH2Cl2/MeOH 97:3); [α]D = – 13.0 (c 1.0, CHCl3); 1H 
NMR (400 MHz, CDCl3): δ 6.33 (d, J = 2.4, 1H), 5.71 (d, J = 2.4, 1H), 4.43-4.36 (m, 
1H), 3.76 (dd, J = 6.4, 2.1, 2H), 2.91-2.83 (m, 1H), 1.87-1.59 (m, 2H), 1.55-1.17 (m, 
12H), 0.88 (t, J = 6.9, 3H); 13C NMR (75 MHz, CDCl3): δ 170.5, 136.4, 123.6, 80.9, 
64.1, 47.0, 36.2, 31.9, 29.5, 29.4, 29.3, 25.1, 22.8, 14.2; IR (film): 3453, 2855, 1764 
1467, 1270; HRMS (ESI+) calculated for C14H25O3 [M+H]+ = 241.1798, found 
241.1793. 
4.4.2. Synthesis of (–)-UB006 via a-methylenation 
(4S,5S)-4-(Hydroxymethyl)-5-octyldihydrofuran-2(3H)-one, (–)-6: 
A cold solution of NaBH4 (0.850 g, 22.37 mmol) in freshly prepared aqueous buffer pH 
= 8 was added to a solution of (R)-4-benzyl-3-((2S,3S)-2-octyl-5-oxotetrahydrofuran-3-
carbonyl)oxazolidin-2-one ((–)-5, 1.5 g, 3.740 mmol) in THF (40 mL) at 0ºC. The 
mixture was stirred for 1 h, then HCl 2 N was added until pH = 4, and the THF was 
evaporated. The resulting residue was extracted with CH2Cl2 (3 x 20 mL). The 
combined organic extracts were washed with NaCl (15 mL), dried (MgSO4), and 
concentrated under reduced pressure. Purification of the residue by flash 
chromatography (hexane/AcOEt 60:40) yielded the desired product (0.770 g, 3.377 
mmol, 90%). Oil: Rf = 0.25 (hexane/AcOEt 1:1); [α]D = – 32.8 (c 1.0, CHCl3); 1H NMR 
(300 MHz, CDCl3): δ 4.39-4.32 (m, 1H), 3.70 (d, J = 5.6, 2H), 2.71-2.59 (m, 1H), 2.50-
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2.30 (m, 2H), 1.82-1.16 (m, 14H), 0.88 (t, J = 6.7, 3H). 13C NMR (101 MHz, CDCl3): δ 
177.1, 83.2, 62.9, 42.6, 35.3, 31.9, 31.6, 29.5, 29.4, 29.3, 25.5, 22.7, 14.2; IR (film): 
3446, 2926, 2855, 1772, 1377, 1359, 1197; HRMS (ESI+) calculated for C13H25O3 [M+H]+ = 
229.1798, found = 229.1797. 
(4S,5S)-4-(Hydroxymethyl)-3-methylene-5-octyldihydrofuran-2(3H)-one, (-)-UB006: 
A commercial solution of BuLi 2.5 M in THF (5.84, 14.6 mmol) was added to a stirred 
solution of diisopropylamine (2.05 mL, 14.6 mmol) in THF (4 mL) at –15ºC under N2, 
and stirred for 15 min. The solution of (4S,5S)-4-(hydroxymethyl)-5-octyldihydrofuran-
2(3H)-one (0.664 g, 2.91 mmol) in THF anh. (5 mL) was added slowly to a solution of 
LDA at –20ºC. After 3 h, the reaction mixture was treated with a slow stream of CO2 
gas for 30 min, and then quenched by addition of HCl 6 N until pH = 2. The resulting 
mixture was allowed to warm to room temperature, then CH2Cl2 (20 mL) and H2O (5 
mL) were added. The aqueous layer was extracted with CH2Cl2 (3 x 20 mL) and 
combined organic extracts were washed with brine (20 mL), dried (MgSO4), and 
concentrated under reduced pressure. The resulting residue was treated with 10 mL of 
stock solution, freshly prepared from 5 mL of acetic acid, 4.5 mL of formalin, 0.15 g of 
AcONa and 1.56 mL of N-methylaniline, and stirred at room temperature for 2 h. The 
reaction mixture was then treated with 10 mL of NaCl sat. and 1 mL of HCl conc. After 
5 min, the resulting residue was thoroughly extracted with CH2Cl2. The organic extracts 
were washed with brine, dried (MgSO4), and concentrated under reduced pressure. The 
purification of the residue by flash chromatography (hexane/AcOEt 80:20) yielded the 
desired product (-)-UB006 (0.450 g, 1.875 mmol, 64%). 
4.4.3. Synthesis of (+)-UB006 
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For the synthesis of (+)-UB006, the same two synthetic procedures were used as for 
(-)-UB006. 
The following intermediates were obtained for the procedure described in Section 4.4.1: 
(2R,3S,4S)-2-Octyl-5-oxo-4-((phenylselanyl)methyl)tetrahydrofuran-3-carboxylic acid: 
[α]D = +54.1 (c 1.0, CHCl3). 
(3S,4R,5R)-4-(Hydroxymethyl)-5-octyl-3-((phenylselanyl)methyl)dihydrofuran-2(3H)-
one: [α]D = +56.4 (c 1.0, CHCl3). 
The following intermediates were obtained for the procedure described in Section 4.4.2: 
(4R,5R)-4-(Hydroxymethyl)-5-octyldihydrofuran-2(3H)-one: [α]D = +31.0 (c 1.0, 
CHCl3). 
(4R,5R)-4-(Hydroxymethyl)-3-methylene-5-octyldihydrofuran-2(3H)-one, (+)-UB006: 
[α]D = +14.2 (c 1.0, CHCl3). 
4.4.4. Synthesis of (±)-UB006 
(2SR,3RS,4RS)-2-Octyl-5-oxo-4-((phenylselanyl)methyl)tetrahydrofuran-3-carboxylic 
acid, (±)-1: 
A solution of (±)-C75 (0.200 g, 0.78 mmol) in EtOH (3 mL) was added dropwise via 
cannula to a mixture of Ph2Se2 (0.135 g, 0.43 mmol) and NaBH4 (0.035 g, 0.94 mmol) 
in EtOH (3 mL) under N2 at r.t. The resulting yellow solution was stirred for 3.5 h and 
HCl 2 N was added until pH = 1. Then, the volatiles were evaporated and the aqueous 
residue was extracted with CH2Cl2 (3 x 8 mL). The combined organic extracts were 
washed with NH4Cl 20% (2 x 5 mL), NaCl sat. (2 x 5 mL) and H2O (5 mL), dried 
(MgSO4), and the solvent was removed under vacuum. Purification of the residue by 
flash chromatography (hexane/AcOEt/AcOH 70:30:1) yielded the desired product 
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(0.290 g, 0.62 mmol, 80%). The product showed identical analytical and spectroscopic 
data to (2S,3R,4R)-2-octyl-5-oxo-4-((phenylselanyl)methyl)tetrahydrofuran-3-
carboxylic acid. 
(3SR,4RS,5RS)-4-(Hydroxymethyl)-5-octyl-3-((phenylselanyl)methyl)dihydrofuran-
2(3H)-one, (±)-2: 
BH3:SMe2 (0.15 mL, 1.42 mmol) was added under N2 at –20ºC to a solution of 
(2SR,3RS,4RS)-2-octyl-5-oxo-4-((phenylselanyl)methyl)tetrahydrofuran-3-carboxylic 
acid (0.45 g, 1.09 mmol) in THF anh. (3.5 mL). The resulting mixture was stirred at –
20ºC for 1 h, 0ºC for 3 h, and r.t. for 18 h. Then, CH2Cl2 (10 mL), buffer pH = 7 and 
NH4Cl sat. at 0ºC were slowly added and stirred for 15 min at 0ºC and 10 min at r.t. The 
layers were separated and the aqueous layer was extracted with CH2Cl2 (3 x 5 mL). 
Afterwards, the combined organic extracts were washed with NaCl (5 mL), dried 
(MgSO4), and concentrated under reduced pressure. Purification of the residue by flash 
chromatography (hexane/AcOEt 75:25) yielded the desired product (0.357 g, 0.91 
mmol, 84%). The product showed identical analytical and spectroscopic data to 
(3R,4S,5S)-4-(hydroxymethyl)-5-octyl-3-((phenylselanyl)methyl)dihydrofuran-2(3H)-
one. 
(4RS,5RS)-4-(Hydroxymethyl)-3-methylene-5-octyldihydrofuran-2(3H)-one, (±)-UB006: 
H2O2 30% (0.061 mL, 0.52 mmol) at r.t. was added to a solution of (3SR,4RS,5RS)-4-
(hydroxymethyl)-5-octyl-3-((phenylselanyl)methyl)dihydrofuran-2(3H)-one (0.053 g, 
0.13 mmol) in THF anh. (0.5 mL). The resulting mixture was stirred for 3 h and then 
CH2Cl2 (5 mL) and H2O (3 mL) were added. The aqueous layer was extracted with 
CH2Cl2 (2 x 5 mL), and combined organic extracts were washed with Na2SO3 (3 mL), 
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dried (MgSO4), and concentrated under reduced pressure. Purification of the residue by 
flash chromatography (hexane/AcOEt 60:40) yielded the desired product (0.023 g, 
0.096 mmol, 72%). The product showed identical analytical and spectroscopic data to 
(-)-UB006. 
4.4.5. Synthesis of (±)-UB339 
(4RS,5SR)-4-(2-Hydroxyethyl)-5-octyldihydrofuran-2(3H)-one, (±)-8: 
BH3:SMe2 (0.055 mL, 0.55 mmol) was added slowly to a stirred solution of 2-
((2SR,3RS)-2-octyl-5-oxotetrahydrofuran-3-yl)acetic acid ((±)-7, 0.100 g, 0.39 mmol) in 
THF anh. (2 mL) at –20ºC under N2. The resulting mixture was stirred at –20ºC for 1 h, 
then 0ºC for 3 h, and r.t. for 18 h. Then, the second portion of BH3:SMe2 (0.055 mL, 
0.55 mmol) at 0ºC was added. After 4 h, the mixture was diluted with CH2Cl2 (10 mL). 
Buffer pH = 7 and NH4Cl sat. at 0ºC were slowly added, and the mixture was stirred for 
15 min at 0ºC and 10 min at r.t. The layers were separated and the aqueous layer was 
extracted with CH2Cl2 (3 x 5 mL). Afterwards, the combined organic extracts were 
washed with NaCl (5 mL), dried (MgSO4), and concentrated under reduced pressure. 
Purification of the residue by flash chromatography (hexane/AcOEt 1:1) yielded the 
desired product (0.062 g, 0.256 mmol, 66%). Oil; Rf = 0.4 (hexane:AcOEt, 1:1); 1H 
NMR (400 MHz, CDCl3): δ 4.13 (td, J = 7.8, 3.9, 1H), 3.76-3.60 (m, 2H), 2.79-2.63 (m, 
1H), 2.38-2.21 (m, 2H), 1.85-1.74 (m, 1H), 1.72-1.18 (m, 15H), 0.86 (t, J = 6.8, 3H); 
13C NMR (101 MHz, CDCl3): δ 176.9, 86.2, 60.6, 38.3, 35.6, 35.4, 34.6, 31.9, 29.5, 
29.3, 25.8, 22.7, 14.2; IR (ATR): 3419, 2923, 2854, 1758, 1188, 1050; HRMS (ESI+) 
calculate for C14H27O3 [M+H]+ = 243.1955, found = 243.1963. 
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(4RS,5SR)-4-(2-Hydroxyethyl)-3-methylene-5-octyldihydrofuran-2(3H)-one, (±)-
UB339: 
A commercial solution of BuLi 2.5 M in THF (0.41 mL, 1.03 mmol) was added to a 
stirred solution of diisopropylamine (0.145 mL, 1.03 mmol) in THF (1 mL) at –15ºC 
under N2 and stirred for 15 min. The solution of (4RS,5SR)-4-(2-hydroxyethyl)-5-
octyldihydrofuran-2(3H)-one (0.050 g, 0.206 mmol) in THF anh. (1.5 mL) was added to 
a solution of LDA at –20ºC. After 3 h, the reaction mixture was treated with a slow 
stream of CO2 gas for 30 min and then quenched by addition of HCl 6 N until pH = 2. 
The resulting mixture was allowed to warm to room temperature, then, CH2Cl2 (10 mL) 
and H2O (5 mL) were added. The aqueous layer was extracted with CH2Cl2 (3 x 10 mL) 
and combined organic extracts were washed with brine (10 mL), dried (MgSO4), and 
concentrated under reduced pressure. The resulting residue was treated with 1.1 mL of 
stock solution that was freshly prepared from 1 mL of acetic acid, 0.75 mL of formalin, 
0.03 g of AcONa, and 0.26 mL of N-methylaniline, and stirred at room temperature for 
2 h. The reaction mixture was then treated with 10 mL of NaCl sat. and 1 mL of HCl 
con. After 5 min, the resulting residue was thoroughly extracted with CH2Cl2. The 
organic extracts were washed with brine, dried (MgSO4), and concentrated under 
reduced pressure. Purification of the residue by flash chromatography (CH2Cl2:AcOEt, 
97:3) yielded the desired product (0.021 g, 0.083 mmol, 40%). Oil; Rf = 0.39 
(CH2Cl2:AcOEt, 95:5); 1H NMR (400 MHz, CDCl3): δ 6.28 (d, J = 2.5, 1H), 5.63 (d, J 
= 2.2, 1H), 4.25 (dt, J = 10.1, 5.2, 1H), 3.77 (t, J = 6.0, 2H), 2.95-2.80 (m, 1H), 1.84 
(dd, J = 13.0, 6.4, 2H), 1.71-1.18 (m, 16H), 0.87 (t, J = 6.8, 3H); 13C NMR (101 MHz, 
CDCl3): δ 170.5, 139.3, 122.6, 83.7, 59.6, 41.5, 36.7, 36.2, 32.0, 29.6, 29.4, 29.3, 25.3, 
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22.8, 14.2; IR (ATR): 3429, 2923, 2853, 1748, 1268, 1119, 1049; HRMS (ESI+) 
calculate for C15H30NO3 [M+NH4]+ = 272.2220, found = 272.2221. 
4.4.6. Synthesis of (±)-UB340 
Dimethyl 2-nonanoylsuccinate, (±)-10: 
Benzoyl peroxide (0.6 g, 1.9 mmol) was added under N2 to a mixture of dimethyl 
maleate (9, 7.72 mL, 61.7 mmol) and n-nonanal (54 mL, 310 mmol). The resulting 
mixture was stirred for 18 h at 80ºC, then the second portion of benzoyl peroxide (0.1 g, 
0.55 mmol) was added and stirred for an additional 3 h at 80ºC. Then, the mixture was 
treated with AcOEt (30 mL) and NaHCO3 sat. (15 mL), and stirred for 15 min. The 
organic layer was washed with H2O (2 x 15 mL) and brine, dried (MgSO4), and 
concentrated under reduced pressure. The n-nonanal was eliminated by distillation 
under reduced pressure and the residue was purified by flash chromatography 
(Hexane:AcOEt, 9:1) to yield the desired product (8.22 g, 28.7 mmol, 48%). Oil; Rf = 
0.53 (CH2Cl2); 1H NMR (CDCl3, 400 MHz): δ 3.99 (dd, J = 6.3, 8.2, 1H), 3.74 (s, 3H), 
3.68 (s, 3H), 2.98 (dd, J = 8.2, 17.6, 1H), 2.84 (dd, J = 6.3, 17.6, 1H), 2.75-2.57 (m, 
2H), 1.64-1.27 (m, 12H), 0.88 (t, J = 6.8, 3H); 13C NMR (CDCl3, 101 MHz): δ 204.1, 
172.0, 169.2, 54.0, 52.9, 52.2, 43.0, 32.4, 32.0, 29.5, 29.3, 29.2, 23.6, 22.8, 14.3; IR 
(film): 2954, 2927, 2856, 1741, 1720, 1457, 1437, 1410, 1367, 1262, 1634, 1012, 668. 
(2SR,3RS)-Methyl 2-octyl-5-oxotetrahydrofuran-3-carboxylate, (±)-11: 
NaBH4 (10 mg, 0.26 mmol) was added to a mixture of dimethyl 2-nonanoylsuccinate 
((±)-10, 0.104 g, 0.36 mmol) in MeOH (5 mL) under N2 at 0ºC. The resulting mixture 
was stirred for 1 h at r.t. Then, conc. HCl (1 drop, pH = 2-3) was added and heated to 
reflux for 1 h. After the volatiles had evaporated, the resulting residue was taken up in 
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CH2Cl2 (10 mL). The organic layer was washed with NaHCO3 (5 mL), H2O (2 x 15 
mL) and brine, dried (MgSO4), and concentrated under reduced pressure. The resulting 
oil was diluted with toluene (5 mL) and DBU (54 µL, 0.36 mmol) was added. The 
mixture was stirred at 100ºC for 12 h. The resulting mixture was washed with HCl 0.02 
N (5 mL) and brine. The organic extract was dried (MgSO4) and concentrated under 
reduced pressure. The residue was purified by flash chromatography (hexane: AcOEt, 
9:1) to afford the desired product (0.082 g, 0.32 mmol, 88%). Oil; Rf = 0.46 
(hexane/AcOEt 7:3); 1H NMR (CDCl3, 300 MHz): δ 4.57 (td, J = 7.3, 5.0, 1H), 3.77 (s, 
3H), 2.92 (dd, J = 17.6, 8.7, 1H), 2.77 (dd, J = 17.6, 9.5, 1H), 1.84-1.64 (m, 2H), 1.59-
1.18 (m, 12H), 0.93-0.84 (m, 3H); RMN de 13C (CDCl3, 101 MHz): δ 174.3, 171.5, 
81.9, 52.6, 45.6, 35.2, 32.1, 31.7, 29.3, 29.1, 29.0, 25.1, 22.6, 14.2; IR (film): 2953, 
2926, 2855, 1790, 1739, 1201; HRMS (ESI+) calculated for C14H28O4 [M+H]+ = 
257.1747, found = 257.1746. 
(2SR,3RS)-2-Octyl-5-oxotetrahydrofuran-3-carboxylic acid, (±)-12: 
NaOH 1 N (8 mL) was added to a stirred solution of (2SR,3RS)-methyl 2-octyl-5-
oxotetrahydrofuran-3-carboxylate ((±)-11, 0.820 g, 3.2 mmol) in THF (8 mL). The 
resulting mixture was stirred for 1 h at 70ºC. Then, CH2Cl2 (20 mL) was added and the 
aqueous layer was washed with CH2Cl2 (2 x 8 mL) and acidified by the addition of con. 
HCl, pH = 1, and heated at 70ºC for 1 h. Then, the mixture was extracted with CH2Cl2 
(4 x 8 mL), and the combined organic extract was washed with brine, dried (MgSO4), 
and concentrated under reduced pressure to give the desired product (0.670 g, 2.77 
mmol, 86%). White solid; mp: 98-100ºC; Rf = 0.24 (hexane/AcOEt/AcOH 8:2:0.1); 1H 
NMR (CDCl3, 400 MHz): d 4.65-4.60 (m, 1H), 3.14-3.07 (m, 1H), 2.95 (dd, J = 8.4, 
17.9, 1H), 2.83 (dd, J = 9.6, 17.9, 1H), 1.86-1.70 (m, 2H), 1.56-1.28 (m, 12H), 0.88 (t, J 
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= 6.7, 3H); 13C NMR (CDCl3, 101 MHz): δ 177.1, 175.7, 83.0, 46.4, 36.3, 32.9, 32.8, 
30.3, 30.2, 30.1, 26.2, 23.6, 15.1; IR (film): 3000-3300, 2925, 2853, 1749, 1718, 1393, 
1243, 1215, 1195, 759, 669; HRMS (ESI+) calculated for C13H22NaO4 [M+Na]+ = 
265.1410, found = 265.1410. 
(4SR,5SR)-4-(Hydroxymethyl)-5-octyldihydrofuran-2(3H)-one, (±)-13: 
BH3:SMe2 (0.370 mL, 3.75 mmol) was added dropwise to a stirred solution of 
(2SR,3RS)-2-octyl-5-oxotetrahydrofuran-3-carboxylic acid ((±)-12, 0.650 g, 2.68 mmol) 
in THF anh. (12 mL) at –20ºC under N2. The resulting mixture was stirred at –20ºC for 
1 h, 0ºC for 3 h, and r.t. overnight. Then, H2O (5 mL) at 0ºC was carefully added. After 
10 min, Na2CO3 sat. (2 mL) and CH2Cl2 (15 mL) at 0ºC were slowly added and the 
layers were separated. The aqueous layer was extracted with CH2Cl2 (3 x 8 mL). 
Afterwards, combined organic extracts were washed with NH4Cl sat. (5 mL) and NaCl 
(5 mL), dried (MgSO4), and concentrated under reduced pressure. The purification of 
the residue by flash chromatography (hexane/AcOEt 1:1) yielded the desired product 
(0.540 g, 2.36 mmol, 88%). Oil; Rf = 0.25 (hexane/AcOEt 1:1); 1H NMR (300 MHz, 
CDCl3): δ 4.39-4.32 (m, 1H), 3.70 (d, J = 5.6, 2H), 2.71-2.59 (m, 1H), 2.50-2.30 (m, 
2H), 1.82-1.16 (m, 14H), 0.88 (t, J = 6.7, 3H); 13C NMR (101 MHz, CDCl3): δ 177.1, 
83.2, 62.9, 42.6, 35.3, 31.9, 31.6, 29.5, 29.5, 29.3, 25.5, 22.7, 14.2; IR (film): 3446, 
2926, 2855, 1772, 1377, 1359, 1197; HRMS (ESI+) calculated for C13H25O3 [M+H]+ = 
229.1798, found = 229.1797. 
(2SR,3RS)-2-Octyl-5-oxotetrahydrofuran-3-carbaldehyde, (±)-14: 
DMSO (0.478 mL, 6.72 mmol) was added dropwise at –78ºC to a stirred solution of 
(COCl)2 (0.465 mL, 5.34 mmol) in CH2Cl2 anh. (5 mL). After 30 min, the solution of 
(4SR,5SR)-4-(hydroxymethyl)-5-octyldihydrofuran-2(3H)-one ((±)-13, 0.506 g, 0.221 
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mmol) in CH2Cl2 anh. (3.5 mL) at –78ºC was added via cannula and stirred for 30 min. 
Then, Et3N anh. (1.5 mL, 10.90 mmol) was added dropwise and stirred at –78ºC for 20 
min and for an additional 15 min at r.t. Subsequently, the inorganic salts were filtered 
with Celite and the volatiles were evaporated. The resulting residue was purified by 
flash chromatography (hexane/AcOEt 1:1) to give the corresponding aldehyde (0.445 g, 
1.97 mmol, 90%). Oil; Rf = 0.52 (hexane/AcOEt 1:1); 1H NMR (400 MHz, CDCl3): δ 
9.72 (d, J = 1.5, 1H), 4.68-4.60 (m, 1H), 3.10 (dddd, J = 9.6, 7.7, 6.4, 1.5, 1H), 2.89 
(dd, J = 18.0, 7.7, 1H), 2.74 (dd, J = 18.0, 9.6, 1H), 1.88-1.61 (m, 2H), 1.55-1.04 (m, 
12H), 0.86 (t, J = 6.8, 3H); 13C NMR (101 MHz, CDCl3): δ 197.4, 174.4, 79.3, 52.6, 
35.6, 31.9, 29.4, 29.3, 29.2, 29.1, 25.2, 22.7, 14.2; IR (film): 3420, 2958, 2925, 2852, 
2727, 1772, 1730, 1362; HRMS (ESI+) calculated for C13H23O3 [M+H]+ = 227.1638, 
found = 227.1642. 
(E)-tert-Butyl 3-((2SR,3SR)-2-octyl-5-oxotetrahydrofuran-3-yl)acrylate, (±)-15: 
A solution of (2SR,3RS)-2-octyl-5-oxotetrahydrofuran-3-carbaldehyde ((±)-14, 0.400 g, 
1.77 mmol) and tert-butyl 2-(triphenylphosphoranylidene)acetate (0.998 g, 2.65 mmol) 
in CH2Cl2 (10 mL) was stirred for 2.5 h at r.t. Then, the resulting solution was washed 
with H2O (5 mL) and brine, dried (MgSO4), and the volatiles were evaporated. Flash 
chromatography (hexane/AcOEt 9:1) of the residue furnished the desired product (0.485 
g, 1.5 mmol 85%). Oil; Rf = 0.21 (hexane/AcOEt 9:1); 1H NMR (300 MHz, CDCl3): δ 
6.70 (dd, J = 15.6, 8.4, 1H), 5.86 (d, J = 15.6, 1H), 4.21 (td, J = 8.3, 3.9, 1H), 2.98-2.84 
(m, 1H), 2.73 (dd, J = 17.4, 8.3, 1H), 2.51 (dd, J = 17.4, 10.6, 1H), 1.78-1.59 (m, 2H), 
1.49 (s, J = 0.6, 9H), 1.44-1.19 (m, 12H), 0.88 (t, J = 6.7, 3H); 13C NMR (101 MHz, 
CDCl3): δ 175.0, 165.0, 143.1, 126.1, 84.1, 81.2, 44.7, 35.3, 34.0, 31.9, 29.5, 29.4, 29.3, 
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28.2, 25.8, 22.8, 14.2; IR (film): 2928, 2856, 1785, 1715, 1655, 1153; HRMS (ESI+) 
calculated for C19H36NO4 [M+NH4]+ = 342.2639, found = 342.2635. 
(E)-3-((2SR,3SR)-2-Octyl-5-oxotetrahydrofuran-3-yl)acrylic acid, (±)-16: 
Trifluoroacetic acid (0.185 mL, 2.40 mmol) and Et3SiH (0.073 mL, 0.462) at room 
temperature were added to a solution of (E)-tert-butyl 3-((2SR,3SR)-2-octyl-5-
oxotetrahydrofuran-3-yl)acrylate ((±)-15, 0.060 g, 0.185 mmol) in CH2Cl2 (1 mL). After 
4 h, another portion of trifluoroacetic acid (0.042 mL, 0.55 mmol) and Et3SiH (0.029 
mL, 0.185 mmol) were added, and stirred for an additional 2 h. Then, the volatiles were 
evaporated and the almost pure product was used without further purification (0.047 g, 
0.17 mmol, 96%). White solid; mp = 94.5-95 °C; Rf = 0.26 (hexane/AcOEt 1:1); 1H 
NMR (400 MHz, CDCl3): δ 10.48 (s, 1H), 6.94 (dd, J = 15.6, 8.5, 1H), 5.96 (d, J = 
15.5, 1H), 4.25 (td, J = 8.0, 4.5, 1H), 3.07-2.84 (m, 1H), 2.78 (dd, J = 17.4, 8.4, 1H), 
2.55 (dd, J = 17.5, 10.4, 1H), 1.75-1.60 (m, 2H), 1.58-1.16 (m, 12H), 0.87 (t, J = 6.8, 
3H); 13C NMR (101 MHz, CDCl3): δ 175.0, 170.7, 147.4, 123.5, 83.9, 44.9, 35.2, 34.1, 
31.9, 29.8, 29.5, 29.4, 29.3, 25.7, 22.8, 14.2; IR (KBr): 3085, 3285-2598, 1770, 1695, 
1625; HRMS (ESI-) calculated for C15H23O4 [M-H]-= 267.1602, found = 267.1592. 
 
3-((2SR,3RS)-2-Octyl-5-oxotetrahydrofuran-3-yl)propanoic acid, (±)-17: 
A solution of (E)-3-((2SR,3SR)-2-octyl-5-oxotetrahydrofuran-3-yl)acrylic acid ((±)-16, 
0.245 g, 0.914 mmol) and Pt/C (5%, 0.071 g, 0.018 mmol) in AcOEt (3 mL, HPLC 
quality) was prepared under N2 at room temperature. Then, the N2 was replaced by H2 
and shaken vigorous for 2.5 h. The suspension was filtered on Celite and washed with 
AcOEt to remove traces of the catalyst. Subsequently, the volatiles were evaporated and 
the product was used without further purification (0.243 g, 0.914 mmol, 100%). White 
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solid; mp = 46.5-47.0 °C; Rf = 0.26 (hexane/AcOEt 1:1); 1H NMR (400 MHz, CDCl3): 
δ 4.11 (td, J = 7.8, 4.0, 1H), 2.78-2.64 (m, 1H), 2.48-2.34 (m, 2H), 2.27-2.14 (m, 2H), 
1.98-1.87 (m, 1H), 1.79-1.57 (m, 3H), 1.57-1.12 (m, 12H), 0.88 (t, J = 6.9, 3H); 13C 
NMR (101 MHz, CDCl3): δ 178.0, 176.3, 85.9, 40.6, 35.1, 34.7, 32.1, 32.0, 29.8, 29.5, 
29.5, 29.3, 27.9, 25.8, 22.8, 14.2; IR (KBr): 2955, 2920, 2855, 1760, 1695, 1219; 
HRMS (ESI+) calculated for C15H27O4 [M+H]+ =271.1904, found = 271.1899. 
 
3-((2SR,3RS)-4-Methylene-2-octyl-5-oxotetrahydrofuran-3-yl)propanoic acid, (±)-18: 
A mixture of 3-((2SR,3RS)-2-octyl-5-oxotetrahydrofuran-3-yl)propanoic acid ((±)-17, 
0.230 g, 0.85 mmol) and a 2 M solution of dimethylmagnesium carbonate in DMF (15 
mL, 30.6 mmol) was prepared and stirred at 135ºC under N2 for 68 h. Subsequently, the 
solution was cooled to room temperature and 6 N HCl (20 mL) and CH2Cl2 (30 mL) 
were added carefully. The layers were separated and the aqueous layer was extracted 
with CH2Cl2 (3 x 5 mL). Then, the combined organic extracts were washed with NaCl 
(5 mL), dried (MgSO4), and concentrated under reduced pressure. The resulting brown 
residue was treated with 5.3 mL of stock solution, freshly prepared from 2.5 mL of 
acetic acid, 2.25 mL of formalin, 0.075 g of AcONa and 0.78 mL of N-methylaniline, 
and stirred at room temperature for 2 h. The reaction mixture was then treated with 10 
mL of NaCl sat. and 1 mL of HCl con. After 5 min, the resulting residue was 
thoroughly extracted with CH2Cl2. The organic extracts were washed with brine, dried 
(MgSO4), and concentrated under reduced pressure. The purification of the residue by 
flash chromatography (CH2Cl2:MeOH, 97:3) yielded the desired product (0.135 g, 
0.476 mmol, 56%). Oil; Rf = 0.35 (CH2Cl2:MeOH 97:3); 1H NMR (300 MHz, CDCl3): 
δ 6.32 (d, J = 2.3, 1H), 5.65 (d, J = 2.3, 1H), 4.22-4.13 (m, 1H), 2.79-2.69 (m, 1H), 2.46 
(t, J = 7.6, 2H), 1.99-1.87 (m, 2H), 1.69-1.55 (m, 2H), 1.53-1.16 (m, 12H), 0.88 (t, J = 
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6.7, 3H); 13C NMR (101 MHz, CDCl3): δ 178.1, 170.1, 138.5, 123.3, 83.2, 43.6, 36.2, 
31.9, 30.6, 29.5, 29.4, 29.3, 28.6, 25.2, 22.8, 14.2; IR (film): 3225, 1762, 1712, 1410, 
1270; HRMS (ESI+) calculated for C16H27O4 [M+H]+ = 283.1904, found = 283.1905. 
3-((2SR,3RS,4RS)-2-Octyl-5-oxo-4-((phenylselanyl)methyl)tetrahydrofuran-3-
yl)propanoic acid, (±)-19: 
A solution of 3-((2SR,3RS)-4-methylene-2-octyl-5-oxotetrahydrofuran-3-yl)propanoic 
acid ((±)-18, 0.051 g, 0.18 mmol) in EtOH (1 mL, 1.3 mmol) was dropwise added via 
cannula to a mixture of Ph2Se2 (0.034 g, 0.11 mmol) and NaBH4 (0.004 g, 0.11 mmol) 
in EtOH (2 mL) under N2 at r.t. The resulting yellow solution was stirred for 4 h, and 
HCl 2 N was added until pH = 1. Then, the volatiles were evaporated and the aqueous 
residue was extracted with CH2Cl2 (3 x 8 mL). The combined organic extracts were 
washed with NH4Cl 20% (2 x 5 mL), NaCl sat. (2 x 5 mL) and H2O (5 mL), dried 
(MgSO4), and the solvent was removed under vacuum. Purification of the residue by 
flash chromatography (CH2Cl2/MeOH, 97:3) yielded the desired product (0.060 g, 
0.136 mmol, 75%). Oil; Rf = 0.45 (CH2Cl2:MeOH 97:3); 1H NMR (400 MHz, CDCl3): δ 
7.65-7.46 (m, 2H), 7.37-7.20 (m, 3H), 4.03 (td, J = 8.1, 3.5, 1H), 3.33 (dd, J = 13.0, 4.5, 
1H), 3.18 (dd, J = 13.0, 6.2, 1H), 2.71 (ddd, J = 9.7, 6.2, 4.5, 1H), 2.30-2.21 (m, 2H), 
2.20-2.08 (m, 1H), 1.86-1.77 (m, 2H), 1.74-1.12 (m, 14H), 0.88 (t, J = 6.8, 3H); 13C 
NMR (101 MHz, CDCl3): δ 177.9, 176.7, 133.3, 129.8, 129.5, 127.7, 83.8, 47.5, 45.0, 
35.3, 32.0, 31.4, 29.8, 29.5, 29.5, 29.3, 27.8, 27.2, 25.8, 22.8, 14.2; IR (film): 3074, 
3052, 1769, 170, 1189; HRMS (ESI+) calculated for C22H33O4Se [M+H]+ = 441.1538, 
found = 441.1544. 
(3RS,4RS,5SR)-4-(3-Hydroxypropyl)-5-octyl-3-((phenylselanyl)methyl)dihydrofuran-
2(3H)-one, (±)-20: 
40	  
	  
BH3:SMe2 (0.016 mL, 0.16 mmol) was added slowly to a stirred solution of 3-
((2SR,3RS,4RS)-2-octyl-5-oxo-4-((phenylselanyl)methyl)tetrahydrofuran-3-
yl)propanoic acid ((±)-19, 0.050 g, 0.11 mmol) in THF anh. (2 mL) at –20ºC under N2. 
The resulting mixture was stirred at –20ºC for 1 h, 0ºC for 3 h, and r.t for 18 h. Then, 
the second portion of BH3:SMe2 (0.016 mL, 0.16 mmol) was added at 0ºC. After 4 h, 
the mixture was diluted with CH2Cl2 (10 mL). Buffer pH = 7 and NH4Cl sat. at 0ºC 
were slowly added and stirred for 15 min at 0ºC and 10 min at r.t. The layers were 
separated and the aqueous layer was extracted with CH2Cl2 (3 x 5 mL). Subsequently, 
the combined organic extracts were washed with NaCl (5 mL), dried (MgSO4), and 
concentrated under reduced pressure. Purification of the residue by flash 
chromatography (hexane/AcOEt 1:1) yielded the desired product (0.032 g, 0.075 mmol, 
67%). Oil; Rf = 0.52 (hexane:AcOEt, 1:1); 1H NMR (400 MHz, CDCl3): δ 7.58-7.49 
(m, 2H), 7.32-7.22 (m, 3H), 4.04 (td, J = 8.3, 3.3, 1H), 3.56 (t, J = 6.2, 2H), 3.33 (dd, J 
= 12.9, 4.7, 1H), 3.20 (dd, J = 12.9, 5.9, 1H), 2.73 (ddd, J = 10.4, 5.8, 4.7, 1H), 2.16-
2.06 (m, 1H), 1.75-1.19 (m, 18H), 0.88 (t, J = 6.8, 3H); 13C NMR (101 MHz, CDCl3): δ 
176.9, 86.2, 60.6, 38.4, 35.6, 35.4, 34.6, 31.9, 29.5, 29.3, 25.8, 22.7, 14.2; IR (ATR): 
3419, 2922, 2853, 1758, 1578, 1187, 1022; HRMS (ESI+) calculated for C15H30O3 
[M+H] + = 427.1745, found = 427.1747. 
(4RS,5SR)-4-(3-Hydroxypropyl)-3-methylene-5-octyldihydrofuran-2(3H)-one 
UB340: 
H2O2 30% (0.026 mL, 0.23 mmol) at r.t. was added to a solution of (3RS,4RS,5SR)-4-
(3-hydroxypropyl)-5-octyl-3-((phenylselanyl)methyl)dihydrofuran-2(3H)-one (0.025 g, 
0.059 mmol) in THF anh. (1 mL). The resulting mixture was stirred for 3.5 h and then 
CH2Cl2 (5 mL) and H2O (3 mL) were added at 0ºC. The aqueous layer was extracted 
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with CH2Cl2 (2 x 5 mL), and the combined organic extracts were washed with Na2SO3 
(3 mL), dried (MgSO4), and concentrated under reduced pressure. Purification of the 
residue by flash chromatography (hexane/AcOEt 70:30) yielded the desired product 
(0.015 g, 0.056 mmol, 95%). Oil; Rf = 0.45 (Hexane:AcOEt, 1:1); 1H NMR (400 MHz, 
CDCl3): δ 6.27 (d, J = 2.5, 1H), 5.60 (d, J = 2.2, 1H), 4.18 (m, 1H), 3.68 (t, J = 5.7, 2H), 
2.72-2.63 (m, 1H), 1.75-1.15 (m, 18H), 0.87 (t, J = 6.8, 3H); 13C NMR (101 MHz, 
CDCl3): δ 170.5, 139.4, 122.5, 83.5, 62.6, 44.4, 36.3, 32.0, 30.5, 29.6, 29.5, 29.4, 29.3, 
25.3, 22.8, 14.2; IR (ATR): 3422, 2925, 2855, 1761, 1268, 1119, 1058; HRMS (ESI+) 
calculated for C16H29O3 [M+H] + = 269.2111, found = 269.2111. 
 
4.3.7. Synthesis of (±)-UB006-CoA 
A solution of hydrate of coenzyme A (13.4 mg, 0.017 mmol) and Na3PO4 ×12H2O (3.5 
mg) in D2O (0.8 mL) was prepared. Then, the pH 8-8.5 was adjusted with KH2PO4. 
Subsequently, the solution was mixed with (±)-UB006 (4.0 mg, 0.017 mmol) and the 
pH was checked again. The progress of the reaction was monitored by 1H NMR. 1H 
NMR (300 MHz, D2O): δ 8.56 (s, 1H), 8.27 (s, 1H), 6.17 (d, J = 6.8, 1H), 4.86-4.73 (m, 
HDO and 2H), 4.61-4.54 (m, 1H), 4.46-4.34 (m, 1H), 4.29-4.17 (m, 2H), 4.02 (s, 1H), 
3.83 (dd, J = 10.0, 5.0, 1H), 3.74 (d, J = 5.0, 2H), 3.55 (dd, J = 9.8, 4.9, 1H), 3.47 (t, J = 
6.5, 3H), 3.37 (t, J = 6.9, 3H), 2.95 (s, 2H), 2.77-2.65 (m, 2H), 2.47 (t, J = 6.6, 2H), 
2.43-2.34 (m, 1H), 1.86-1.71 (m, 1H), 1.72-1.58 (m, 1H), 1.50-1.09 (m, 12H), 0.91-0.81 
(m, 4H), 0.74 (s, 3H). HRMS (ESI-) calculated for C35H57DN7O19P3S [M-2H]2- = 
503.1394, found = 503.1394. 
4.5. Expression of CPT1A in Saccharomyces cerevisiae 
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Rat CPT1A was expressed in yeast cells, and mitochondrial cell extracts were 
obtained as previously described [38]. 
4.6. Determination of carnitine acyltransferase activity 
Mitochondrial-enriched fractions were obtained by differential centrifugation 
[39], with minor modifications. All protein concentrations were determined using the 
Bio-Rad protein assay with bovine serum albumin as a standard. 
A radiometric method was used for the assay of carnitine acyltransferase, as 
described previously [40]. The activity was assayed in mitochondrial-enriched fractions 
obtained from yeast (3–4 µg protein) and from rat hypothalamus (100 µg protein). 
Enzyme activity was assayed for 5 min at 30°C in a total volume of 200 µL. The 
substrates were 400 µM L-carnitine, and 50 µM palmitoyl-CoA. In the in vitro studies, 
the enzyme was preincubated with increasing concentration of drugs (0.1-100 µM) for 1 
min. The values obtained were used to estimate the IC50 value. This value corresponds 
to the concentration that inhibits 50% of the enzymatic activity. In all cases, the molar 
ratio of acyl-CoA to albumin was kept at 5:1, to avoid the presence of free acyl-CoA 
and its deleterious detergent effects, and to prevent the formation of micelles. 
4.7. Determination of spectrophotometric and radiometric FAS activity 
For the in vitro experiments, FAS was purified from rat liver following the 
protocol described by Linn [41]. However, in our experimental conditions, DTT was not 
added. For the FAS activity assay, a spectrophotometric method was used [42]. 
Cytosolic hepatic extracts obtained from rat (315 µg) were preincubated at 30°C for 30 
min with an increasing concentration of drugs: (±)-C75, (±)-UB006, (+)-UB006, (−)-
UB006, (±)-UB339, (±)-UB340 dissolved in DMSO (100 – 5000 µM), using DMSO as 
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a blank. NADPH (121 µM) and acetyl-CoA (61 µM) in potassium phosphate buffer (pH 
= 7.2) were added to preincubated enzyme and equilibrated at 37°C for 3 min. The 
reaction was initiated by the addition of malonyl-CoA (55 µM). The total reaction 
volume was 0.33 mL. The oxidation of NADPH was followed at 340 nm and 37°C for 
10 min. Drug concentrations ranging from 100 to 5000 µM were used to estimate the 
IC50 value.  
The inhibitory effect of (−)-UB006 on FAS activity in OVCAR3 cell cultures was 
analysed by a radiometric method. FAS activity was assayed by measuring the 
incorporation of radiolabelled malonyl-CoA into palmitate [43]. 10-cm plates with 2.5 x 
106 cells were treated with (−)-UB006 (29.7 µM) for 2 hours, using DMSO as a control. 
Tissue samples were homogenized into 20 mM Tris-HCl (pH 7.5), 1 mM DTT, 1 mM 
MgCl2 and 1 mM EDTA, and centrifuged at 14,000·g for 30 min at 4°C. Sample 
protein content was determined using the BCA protein assay (#23228, 
ThermoScientific). A total of 320 µg of protein extracts from each sample were 
preincubated for 10 min at 37ºC. Subsequently, reaction buffer components were added 
to a final concentration of 0.225 mM NADPH, 0.024 mM acetyl-CoA, 0.64 mM 
malonyl-CoA and 0.05 µCi/sample 14C-malonyl-CoA (NEC6122005UC, Perkin Elmer) 
and incubated for 10 min at 37ºC. Reactions were stopped by adding 100 µL 0.5 N 
NaOH to the 500 µL reaction mix. Then samples were saponified by boiling them for 
15 min at 100ºC and then neutralized by adding 100 µL 1 N HCl. After 3 n-pentane 
extractions, samples were dried with N2 flow, resuspended in 0.5 mL pentane and 
analysed by scintillation counting.  
 
4.8. Cell cultures and viability assays 
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MCF-7 (human breast adenocarcinoma), SKBr3 (human breast 
adenocarcinoma), OVCAR-3 (human ovary carcinoma), MIAPaCa-2 (human pancreas 
carcinoma), PC3 (human prostate adenocarcinoma), MDA-MB-231 (human breast 
cancer adenocarcinoma) and HCT116 (human colorectal carcinoma) cell lines were 
obtained from ATCC. Cells were cultured at 37°C in a humidified atmosphere of 5% 
CO2 in complete medium composed of Ham’s F12 supplemented with 10% heat-
inactivated fetal bovine serum (FBS), 100 units/mL penicillin and 100 µg/mL 
streptomycin. The cultures were passaged once or twice a week by gentle trypsinization, 
and cells were grown to confluence in 10 cm culture dishes. 
To evaluate the cytotoxic effect of the drugs, an MTT cytotoxicity assay was 
performed. A total of 4–8 × 103 cells/well were plated in 96-well plates in 100 µL of 
culture medium. Once the cells had attached to the plate, the medium was removed and 
cells were incubated for 72 h in fresh medium with a different concentration (1.25, 2.5, 
5, 10, 15, 20 and 30 µg/mL) of drugs. DMSO was used as a blank, at a final 
concentration ≤ 0.2%. Then, the cells were incubated for 3 h with 100 µL of fresh 
medium and 20 µL of MTT dissolved in PBS at 5 µg/mL concentration. Following 
treatment, the supernatants were carefully removed and the MTT-formazan crystals, 
formed by metabolically viable cells, were solubilized by adding 100 µL/well of 
DMSO. Absorbance was measured at 570 nm. 
4.9. Determination of fatty acid synthesis pathway activity  
OVCAR3 cells were plated at 5 x 104/well in 1 mL of the medium in 24-well 
plates and incubated overnight. Then, the medium was changed for a fresh medium 
without serum. Fatty acid synthesis was assayed with a 2-h pulse of [U-14C]-acetate (1 
µC) after 2 h of drug exposure. Then, Folch extraction of lipids and scintillation 
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counting was carried out [44]. All determinations were performed in triplicate. Data are 
represented as mean ± SEM.  
4.10. Metabolic extracellular flux analysis 
The Seahorse XF24 Analyzer (Seahorse Bioscience, Agilent) was used to 
measure oxygen consumption rate (OCR) in OVCAR3 cells. Cells were plated at 5 x 
104/well 100 µL in 24-well plates and treated with (−)-UB006 (29.74 µM) (or 
equivalent DMSO as a control) for 24 h. For a typical bioenergetic profile, we used 
oligomycin to block ATP synthase; the uncoupler carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone (FCCP) to measure maximal respiratory capacity; 
and then antimycin-A to leave only non-mitochondrial activity to be measured (all from 
Sigma-Aldrich). Before the measurement, cells were incubated for 1 hour with XF 
Assay Medium (Seahorse Bioscience) plus 5 mM glucose. During the assay, we 
injected the following at the final concentrations in the injection port: 2 µg/mL 
oligomycin, 0.3 µM FCCP and 1 µM antimycin A. OCR was calculated by plotting the 
O2 tension of media as a function of time (pmol/min), and data were normalized by the 
protein concentration measured in each individual well. The results were quantified as 
the average of 8–10 wells ± SEM per time point in at least three independent 
experiments. 
4.11. Analysis of mRNA expression by quantitative real-time PCR 
Total RNA was isolated from OVCAR-3 cells treated with (−)-UB006 (29.74 
µM), using an Illustra MiniRNA Spin kit (GE Healthcare). cDNA was obtained using a 
Transcriptor First Strand cDNA Synthesis kit (Roche), following the manufacturer’s 
instructions. Relative quantification of mRNA was performed with a LightCycler® 480 
instrument (Roche) in 10 µL of reaction medium, using 8.25 ng of cDNA, forward and 
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reverse primers at 100 nM each, and a SYBR Green PCR Master Mix Reagent kit (Life 
Technologies). The primer pairs were as follows: casp3 (for: 
TGAGTGCTCGCAGCTCATA; rev: GGGCTCGCTAACTCCTCAC); ddit4 (for: 
GCTTAGGGGCCAACAAGG; rev: TCTGGATGTCACACCACTGTT); bip (for: 
AATGACCAGAATCGCCTGAC; rev: CGCTCCTTGAGGTTTTTGTC) and 18s (for: 
GCAATTATTCCCCATGAACG; rev: GGGACTTAATCAACGCAAGC). The mRNA 
levels were normalized to those of 18s and expressed as fold change. 
 
4.12. Western blot analysis 
OVCAR-3 cells were cultured at 1x105 cells/well in 2 mL in 6-well plates and 
treated with (−)-UB006 (29.74 µM) (or equivalent DMSO as a control) for 24 h. Cells 
were harvested in lysis buffer and the protein concentration was determined using a 
BCA protein assay kit (Thermo). Samples were separated on 8% or 12% SDS-PAGE 
gels, depending on the molecular weight of the protein of interest, and then transferred 
onto PVDF membranes (Millipore). The following primary antibodies and dilutions 
were used: cleaved caspase-3 (1:1000; Cell Signalling, #9664), translocase of the 
mitochondrial inner membrane (TIM)-44 (1:5000; BD Biosciences, #612582), cleaved 
caspase-2 (1:1000; Cell Signalling, #2224), p70 S6 kinase (1:1000; Santa Cruz, sc-230), 
phospho-p70 S6 kinase (1:1000; Cell Signalling, #9205) and β-actin (1:10,000; Sigma 
A3854). Blots were incubated with the appropriate IgG-HRP-conjugated secondary 
antibody. Protein bands were visualized using the ECL immunoblotting detection 
system (GE Healthcare) and developed on an ImageQuant LAS4000 system (GE 
Healthcare). For the analysis of protein expression, bands from at least three 
independent experiments were quantified by densitometry, using Image J analysis 
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software.
48	  
	  
  
Acknowledgments 
This study was supported by the Ministry of Spain - MINECO (SAF2014-
52223-C2-1-R to JG and DS, cofunded by the Fondos Europeos de Desarrollo Regional 
de la Unión Europea [FEDER] and SAF2013-45887-R to LH), the Centro de 
Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición 
(CIBEROBN) (Grant CB06/03/0001 to DS), the Generalitat de Catalunya 
(2014SGR465 to DS), Fundació Marató TV3 to DS and the European Foundation for 
the Study of Diabetes (EFSD)/Janssen-Rising Star and L’Oréal-UNESCO “For Women 
in Science” research fellowships to LH. KM is grateful to IBUB (Universitat de 
Barcelona) for a fellowship. We thank Dr. Antonio Zorzano and Dr. David Sebastián for 
assistance with the extracellular flux analysis. 
 
Conflict of interest 
The authors declare no conflict of interest. 
49	  
	  
 
REFERENCES 
[1]   E.S. Pizer, F.D. Wood, H.S. Heine, F.E. Romantsev, G.R. Pasternack, F.P. Kuhajda, 
Inhibition of fatty acid synthesis delays disease progression in a xenograft model of 
ovarian cancer, Cancer Res. 56 (1996) 1189–1193. 
[2]  S.F. Jones, J.R. Infante, Molecular pathways: fatty acid synthase, Clin. Cancer Res. 21 
(2015) 5434–5438. 
[3]  C.F. Semenkovich, Regulation of fatty acid synthase (FAS), Prog. Lipid Res. 36 (1997) 
43–53. 
[4]  C. Turrado, T. Puig, J. García-Cárceles, M. Artola, B. Benhamú, S. Ortega-Gutiérrez, J. 
Relat, G. Oliveras, A. Blancafort, D. Haro, P.F. Marrero, R. Colomer, M.L. López-
Rodríguez, New synthetic inhibitors of fatty acid synthase with anticancer activity, J. 
Med. Chem. 55 (2012) 5013–5023. 
[5]  G.E. Mullen, L. Yet, Progress in the development of fatty acid synthase inhibitors as 
anticancer targets, Bioorg. Med. Chem. Lett. 25 (2015) 4363–4369. 
[6]  F.P. Kuhajda, E.S. Pizer, J.N. Li, N.S. Mani, G.L. Frehywot, C.A. Townsend, Synthesis 
and antitumor activity of an inhibitor of fatty acid synthase, Proc. Natl. Acad. Sci. USA 
97 (2000) 3450–3454.  
[7] E.S. Pizer, F.J. Chrest, J.A. DiGiuseppe, W.F. Han, Pharmacological inhibitors of 
mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor 
cell lines, Cancer Res. 58 (1998) 4611–4615.  
[8]  A. Bentebibel, D. Sebastian, L. Herrero, E. Lopez-Vinas, D. Serra, G. Asins, P. Gomez-
Puertas, F.G. Hegardt, Novel effect of C75 on carnitine palmitoyltransferase I activity 
50	  
	  
and palmitate oxidation, Biochemistry 45 (2006) 4339–4350.  
[9]  P. Mera, A. Bentebibel, E. López-Viñas, A.G. Cordente, C. Gurunathan, D. Sebastián, I. 
Vázquez, L. Herrero, X. Ariza, P. Gómez-Puertas, G. Asins, D. Serra, J. Garcia, F.G. 
Hegardt, C75 is converted to C75-CoA in the hypothalamus, where it inhibits carnitine 
palmitoyltransferase 1 and decreases food intake and body weight, Biochem. Pharmacol. 
77 (2009) 1084–1095.  
[10]  J.D. McGarry, N.F. Brown, The mitochondrial carnitine palmitoyltransferase system. 
From concept to molecular analysis, Eur. J. Biochem. 244 (1997) 1–14.  
[11]  B. Kasprzyk-Hordern, Pharmacologically active compounds in the environment and their 
chirality. Chem. Soc. Rev. 39 (2010) 4466–4503.  
[12]  N.B. Fedorov, L.C. Benson, J. Graef, P.M. Lippiello, M. Bencherif, Differential 
pharmacologies of mecamylamine enantiomers: positive allosteric modulation and 
noncompetitive inhibition, J. Pharmacol. Exp. Ther. 328 (2009) 525–532.  
[13]  K. Chakrabarty, C. Forzato, P. Nitti, G. Pitacco, E. Valentin, The First Kinetic 
Enzymatic resolution of methyl ester of C75, Lett. Org. Chem. 12 (2010) 245–248.  
[14]  K. Makowski, P. Mera, D. Paredes, L. Herrero, X. Ariza, G. Asins, F.G. Hegardt, J. 
Garcia, D. Serra, Differential pharmacologic properties of the two C75 enantiomers: (+)-
C75 is a strong anorectic drug; (-)-C75 has antitumor activity, Chirality 25 (2013) 281–
287.  
[15]  M. Amador, X. Ariza, J. Garcia, J. Ortiz, A straightforward synthesis of (-)-phaseolinic 
acid, J. Org. Chem. 69 (2004) 8172–8175.  
[16]  M.M. Murta, M.B.M. de Azevedo, A.E. Greene, An improved procedure for alfa-
methylenation of lactones, Synth. Commun. 23 (1993) 495–503.  
[17]  W.L. Parker, F. Johnson, Total synthesis of dl-avenaciolide, J. Org. Chem. 38 (1973) 
51	  
	  
2489–2496.  
[18]  T.M. Patrick, The free radical addition of aldehydes to unsaturated polycarboxylic esters, 
J. Org. Chem. 17 (1952) 1009–1016.  
[19]  E.S. Pizer, C. Jackisch, F.D. Wood, G.R. Pasternack, N.E. Davidson, F.P. Kuhajda, 
Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer 
cells, Cancer Res. 56 (1996) 2745–2747.  
[20]  Y. Zhan, N. Ginanni, M.R. Tota, M. Wu, N.W. Bays, V.M. Richon, N.E. Kohl, E.S. 
Bachman, P.R. Strack, S. Krauss, Control of cell growth and survival by enzymes of the 
fatty acid synthesis pathway in HCT-116 colon cancer cells, Clin. Cancer Res. 14 (2008) 
5735–5742.  
[21]   K. Tomek, R. Wagner, F. Varga, C.F. Singer, H. Karlic, T.W. Grunt. Blockade of fatty 
acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase 
signaling proteins in ovarian cancer, Mol. Cancer Res. 9 (2011) 1767–1779. 
[22]  J.N. Li, M. Gorospe, F.J. Chrest, T.S. Kumaravel, M.K. Evans, W.F. Han, E.S. Pizer, 
Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and 
cytotoxic effects modulated by p53, Cancer Res. 61 (2001) 1493–1499.  
[23]  E.S. Pizer, J. Thupari, W.F. Han, M.L. Pinn, F.J. Chrest, G.L. Frehywot, C.A. 
Townsend, F.P. Kuhajda, Malonyl-coenzyme-A is a potential mediator of cytotoxicity 
induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts, 
Cancer Res. 60 (2000) 213–218.  
[24] W. Zhou, P.J. Simpson, J.M. McFadden, C.A. Townsend, S.M. Medghalchi, 
A.Vadlamudi, M.L. Pinn, G.V. Ronnett, F.P. Kuhajda, Fatty acid synthase inhibition 
triggers apoptosis during S phase in human cancer cells, Cancer Res. 63 (2003) 7330–
7337.  
52	  
	  
[25]  R. Ventura, K. Mordec, J. Waszczuk, Z. Wang, J. Lai, M. Fridlib, D. Buckley, G. 
Kemble, T.S. Heuer, Inhibition of de novo palmitate synthesis by fatty acid synthase 
induces apoptosis in tumor cells by remodeling cell membranes, inhibiting signaling 
pathways, and reprogramming gene expression, EBioMedicine 2 (2015) 808–824.   
[26] C.-S.Yang, K. Matsuura, N.-J. Huang, A.C. Robeson, B. Huang, L. Zhang, S. Kornbluth, 
Fatty acid synthase inhibition engages a novel caspase-2 regulatory mechanism to induce 
ovarian cancer cell death, Oncogene 34 (2015) 3264–3272.   
[27]  A. Sofer, K. Lei, C.M. Johannessen, L.W. Ellisen, Regulation of mTOR and cell growth 
in response to energy stress by REDD1, Mol. Cell. Biol. 25 (2005) 5834–5845.   
[28]  T. Shoshani, A. Faerman, I. Mett, E. Zelin, T. Tenne, S. Gorodin, Y. Moshel, S. Elbaz, 
A. Budanov, A. Chajut, H. Kalinski, I. Kamer, A. Rozen, O. Mor, E. Keshet, D. 
Leshkowitz, P. Einat, R. Skaliter, E. Feinstein, Identification of a novel hypoxia-
inducible factor 1-responsive gene, RTP801, involved in apoptosis, Mol. Cell. Biol. 22 
(2002) 2283–2293.  
[29]  J.E. Ricci, R.A. Gottlieb, D.R. Green, Caspase-mediated loss of mitochondrial function 
and generation of reactive oxygen species during apoptosis, J. Cell. Biol. 160 (2003) 65–
75.   
[30]  T.M. Loftus, D.E. Jaworsky, G.L. Frehywot, C.A. Townsend, G.V. Ronnett, M.D. Lane, 
F.P. Kuhajda, Reduced food intake and body weight in mice treated with fatty acid 
synthase inhibitors, Science 288 (2000) 2379–2381.   
[31]  H. Orita, J. Coulter, E. Tully, F.P. Kuhajda, E. Gabrielson, Inhibiting fatty acid synthase 
for chemoprevention of chemically induced lung tumors, Clin. Cancer Res. 14 (2008) 
2458–2464.   
[32] J.M. McFadden, S.M. Medghalchi, J.N. Thupari, M.L. Pinn, A. Vadlamudi, K.I. Miller, 
53	  
	  
C.A. Townsend, F.P. Kuhajda, Application of a flexible synthesis of (5R)-
thiolactomycin to develop new inhibitors of type I fatty acid synthase, J. Med. Chem. 48 
(2005) 946–961.  
[33]  M. López, C.J. Lelliott, A. Vidal-Pui, Hypothalamic fatty acid metabolism: a 
housekeeping pathway that regulates food intake, BioEssays 29 (2007) 248–261.  
[34]  P. Dowel, Z. Hu, M.D. Lane, Monitoring energy balance: metabolites of fatty acid 
synthesis as hypothalamic sensors, Annu. Rev. Biochem. 74 (2005) 515–534.   
[35]  Z. Hu, Y. Dai, M. Prentki, S. Chohnan, M.D. Lane, A role for hypothalamic malonyl-
CoA in the control of food intake, J. Biol. Chem. 280 (2005) 39681–39683.   
[36]  S. Obici, Z. Feng, K. Morgan, D. Stein, G. Karkanias, L. Rossetti, Central administration 
of oleic acid inhibits glucose production and food intake, Diabetes 51 (2002) 271–275.  
[37]  G. Paxinos, C. Watson, The Rat Brain: in Stereotaxic Coordinates. fourth ed., Academic 
Press, San Diego, 1998.   
[38]  M. Morillas, P. Gómez-Puertas, A. Bentebibel, E. Sellés, N. Casals, A. Valencia, F.G. 
Hegardt, G. Asins, D. Serra, Identification of conserved amino acid residues in rat liver 
carnitine palmitoyltransferase I critical for malonyl-CoA inhibition. Mutation of 
methionine 593 abolishes malonyl-CoA inhibition, J. Biol. Chem. 278 (2003) 9058–
9063.   
[39]  J.M. Graham, D. Rickwood, Subcellular Fractionation: A Practical Approach, Oxford 
University Press, USA, 1997.  
[40]  M. Morillas, P. Gómez-Puertas, R. Roca, D. Serra, G. Asins, A. Valencia, F.G. Hegardt, 
Structural model of the catalytic core of carnitine palmitoyltransferase I and carnitine 
octanoyltransferase (COT): Mutation of CPT I histidine 473 and alanine 381 and COT 
alanine 238 impairs the catalytic activity, J. Biol. Chem. 276 (2001) 45001–45008.  
54	  
	  
[41]  T.C. Lin, Purification and crystallization of rat liver fatty acid synthetase, Arch. 
Biochem. Biophys. 209 (1981) 613–619.   
[42] C.J. Lelliott, M. Lopez, R.K. Curtis, N. Parker, M. Laudes, G. Yeo, M. Jimenez-Liñan, J. 
Grosse, A.K. Saha, D. Wiggins, D. Hauton, M.D. Brand, S. O’Rahilly, J.L. Griffin,  
G.F. Gibbons, A. Vidal-Puig, Transcript and metabolite analysis of the effects of 
tamoxifen in rat liver reveals inhibition of fatty acid synthesis in the presence of hepatic 
steatosis, FASEB J. 19 (2005) 1108–1119.  
 [43]  M.J. Arslanian, S.J. Wakil, Fatty acid synthase from chicken liver, Methods Enzymol. 35 
(1975) 59–65. 
[44]  J. Folch, M. Lees, G.H. Sloane Stanley, A simple method for the isolation and 
purification of total lipides from animal tissues, J. Biol. Chem. 226 (1957) 497–509.  
  
  
  
  
 
 
